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Abstract 
Cross-Sectional Cohort Separation of AV1451 Uptake Patterns using Voxel-wise Barycentric 
Discriminant Analysis (VoBADA) 
Ian A. Kennedy 
Michael D. Devous, PhD 
 Alzheimer’s disease (AD) is expected to affect 1 out of 85 people by 2050, and with no 
currently-available disease-modifying treatment, understanding the underlying pathology 
which is hypothesized to bring about AD is critical for research and development of novel 
drugs to prevent the onset and progression of the disease. AD is believed to be caused by an 
accumulation of beta amyloid plaques in the grey cortex which brings about the 
destabilization of tau protein in neuronal microtubules, leading to apoptosis and regional 
atrophy. As definitive diagnosis of AD can only be made at autopsy, understanding disease 
pathology and developing tools to aid in more accurate, earlier diagnosis becomes imperative 
to developing disease-modifying treatments.  
The tau-specific PET tracer AV1451 is utilized to understand in vivo information 
regarding tau accumulation and propagation. To quantify the differential diagnostic 
capabilities of AV1451 in differentiating between AD and other clinical diagnoses, voxel-
wise barycentric discriminant analysis (VoBADA), an extension of multi-block barycentric 
discriminant analysis (MUBADA) is utilized on a battery of 202 subjects. Groups were 
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defined by paired amyloid status as assessed by Amyvid PET scans and by clinical diagnosis 
which categorized the patients as either cognitively normal, mild cognitive impairment 
(MCI), or Alzheimer’s disease (AD). Old cognitively normal (OCN) and young cognitively 
normal (YCN) subjects were defined based on age 50. Final groups selected were amyloid 
negative OCN, MCI, & AD and amyloid positive MCI & AD. Images were normalized by 
grey cerebellum counts and vectorised using a whole brain mask. The factor space was 
generated by running a generalized principal component analysis (GPCA) on the mean 
centered data. A combination of the Scree test, percentage of total variance, and 
bootstrapping the decomposition revealed that the first dimension is the sole dimension 
worth investigating to determine variance between clinical groups. Projecting the individual 
subjects onto the factor space through fixed effects modeling and random effects modeling 
(through jackknifing) revealed the distribution of factor scores across the first dimension. A 
general trend of separation was seen between the amyloid negative groups, the amyloid 
positive MCIs, and the amyloid positive ADs, but two much variance within the amyloid 
positive groups prevented a significant separation from being realized. This was also reflected 
when calculating accuracy of group assignment: while fixed effects modeling showed a 
better-than chance classification through a Chi-square test (p = 0.0139), random effects 
modeling did not yield significant classification (p = 0.0528). To better focus on voxels which 
contribute to group separation, a partial inertia map was generated for the first dimension 
based on the “eigenbrain” from the decomposition with weights for each voxel 
corresponding to the degree of separation between groups for that voxel. To ensure that the 
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weights were only corresponding to moving in a direction towards AD, the “eigenbrain” was 
bootstrapped and pseudo-standard scores were generated. Significant weights are found in 
the temporal, parietal, occipital, and frontal lobes. While the accuracy of distinguishing 
between groups is moderate in the random effects model, it only reflects the separation 
quality of the voxels within the whole brain. The significant voxels extracted from the 
bootstrapped “eigenbrain” can be used in further analyses to better classify subjects which fit 
an AD-like pattern of uptake. Focusing on these voxels in quantitative analyses and 
qualitative reads can better assist in the diagnosis of AD. 
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1. INTRODUCTION 
Alzheimer’s disease (AD) is expected to become a major public health concern, 
affecting 1 out of 85 people globally by 2050 [1]. With no currently-approved cure, 
understanding the pathology of AD’s biomarkers is imperative to the development of disease-
modifying treatments. 
Diagnosis of AD can only be properly determined at autopsy, creating a difficult 
challenge in assessing the disease state in vivo and any changes brought on by disease-
modifying treatments. This is circumvented through positron emission tomography (PET) 
imaging of two of AD’s biomarkers: beta amyloid plaques and paired helical filaments (PHFs) 
of hyper-phosphorylated tau tangles [2]. While amyloid imaging has been associated with 
cognitive decline and progression of Alzheimer’s disease [3, 4], none of the FDA approved 
amyloid-specific radiotracers have been approved for determining an AD diagnosis—they 
can only be used to rule out AD [5, 6]. In addition, amyloid accumulation is present in other 
disorders such as amyloidosis [7], making an accurate stand-alone diagnosis difficult. PHFs, 
on the other hand, are theorized as specific to AD with other forms of tau aggregates present 
in other tauopathies [8]. 
AV1451 has preferential binding to PHFs in the grey cortex with low binding 
potential in the white matter and non-cortical areas [9]. AV1451 has already been assessed as 
having potential for differential diagnosis [9], but a more thorough approach with more 
subjects is necessary for a more complete understanding. 
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Multi-block barycentric discriminant analysis (MUBADA) is a principal component 
analysis (PCA) derivative which incorporates ANOVA-like features by loading subjects based 
on pre-defined groups and running a singular value decomposition (SVD) on the means to 
create a factor space [10]. Then, further analyses can be performed such as the assessment of 
group classification accuracy, separation of groups based on important dimensions or 
features, and the extraction of a volume of interest (VOI) which corresponds to overall group 
separation for use in other studies. The goal of this project is to extend MUBADA into a 
voxel-wise analysis procedure (VoBADA) to assess the differential diagnosis capabilities of 
AV1451 based on groups comprised of both clinical diagnosis and beta amyloid status as 
assessed through amyloid PET imaging. 
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2. BACKGROUND 
2.1 PET Imaging and Analysis 
 PET imaging utilizes the administration of radiotracers, ligands with chemically-
bound radioisotopes, into a patient’s bloodstream. Following a tracer-dependent waiting 
period, patients are placed into a scanner where scans are acquired as the tracer undergoes β+ 
decay and releases photons through positron-electron annihilation. The gamma photons are 
picked up by a scintillator and a three-dimensional image is reconstructed using an algorithm 
specific to the scanner model. 
 Once the image has been generated, it can be read by a physician to assist in 
diagnosis, or be analyzed to understand regional function for the radiotracer of interest. As a 
3D image, voxels (volumetric pixels) can be examined to provide a more local estimate of 
function. However, voxels can be more prone to noise depending on reconstruction 
parameters such as matrix size and the inherent point spread function (PSF) of the scanner 
[12]. The PSF can be problematic as it can cause spillover from different tissue types such as 
grey matter, white matter, and cerebrospinal fluid. Pairing a large PSF with low spatial 
resolution can cause substantial partial volume effects (PVEs) within the PET scan. Partial 
volume correction algorithms exist and are a prominent area of research within the nuclear 
medicine field [12, 13, 14]. However, they will not be explored as part of this project. Motion 
during scan acquisition can act as another source of potential error when analyzing PET 
images. This is especially a problem with cognitively impaired patients who may experience 
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more discomfort throughout the scan, or may forget instructions to lie still [15]. Post-
reconstruction correction is the best approach to motion correction as photons can be 
corrected as detected [16]. However, pre-reconstruction motion correction techniques are 
not available on all scanners. Post-reconstruction techniques involve co-registering each 
frame of the acquisition to one of the frames, such as the first frame, or the average of the 
frames. This approach is problematic as it does not correct for within-frame motion [17]. 
Each frame is the accumulation of counts within a certain interval of time, say 5 or 10 
minutes. If a patient were to move within that time span, post-reconstruction motion 
correction techniques would be fruitless. Within-frame motion can lead to blurring which 
distorts boundaries and leads to additional partial volume effects which cannot be corrected 
through partial volume correction (PVC) algorithms. 
 Due to inherent differences across PET scanners, PET scans cannot be directly 
compared across subjects. Multi-center studies become important in clinical trials as results 
can be more directly projected to the general population due to the diversity of scanners used 
in clinics across the country. One way to overcome the noise is to generate standard uptake 
values, or SUVs. These are calculated by multiplying the tissue radioactivity concentration in 
mega Becquerels (MBq) per kg (denoted c in Equation 1) by the ratio of the patient’s weight 
in kg to the injected dose in MBq [18]. 
SUV = c ∗ weightdose                                                           (Eqn 1) 
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The tissue radioactivity concentration can be modeled either by the individual voxel values 
or by the mean counts within a predefined VOI. VOIs can either be created based on 
anatomical boundaries, or through statistical and other data-driven approaches. However, 
SUVs can be substantially affected by the noise within the PET scan. A common approach to 
overcome the noise is to divide voxel counts and mean region counts by the average value of 
a reference region—these are referred to as SUVrs. Larger reference regions provide more 
stability in their value than looking at SUVs. The key, though, is selecting the correct 
reference region. This is usually based on a priori information regarding the target molecule. 
For example, 18F- Flurodeoxyglucose, or FDG, binds to glucose receptors and is used estimate 
metabolic activity in the grey cerebrum. Neurodegenerative diseases like AD and fronto-
temporal dementia (FTD) induce hypometabolism through regional atrophy in the grey 
cortex. The cerebellum is spared, though, making the grey cerebellum a good candidate for a 
reference region [19]. Sometimes reference region selection is non-trivial, and may be 
selected based on whether cross-sectional or longitudinal studies are being performed [20, 
21]. When multiple subjects are involved in a study, it is common to warp PET scans to a 
template space such as the one defined by the Montreal Neurological Institute (MNI). This is 
based on the Talairach atlas which is defined from averages of dissected brain slices [22]. The 
original MNI atlas is based on a two-pass fitting scheme. First, 241 T1 MRIs from healthy 
subjects were manually aligned to each other and to match regional outlines specified by the 
Talairach atlas. Then, 305 T1 MRIs from healthy subjects were linearly fit to the 241 
template and then averaged [22]. A third template generated from 152 normal MRIs in a 
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similar manner has been adopted as the standard and is used in various neuroimage 
processing softwares like SPM and FSL—this template is displayed in a montage in Figure 2-
1. The 152 template will be referred to henceforth as the MNI template. PET images can 
either be warped directly to the template or assisted in their registration through a second 
modality such as T1 or T2 MRI if their uptake topology does not create reasonable 
boundaries for fitting. In addition, two separate MNI templates exist depending on the 
desired spatial resolution: one with voxel sizes of 2mm x 2mm x 2mm and one with voxel 
sizes of 1mm x 1mm x 1mm. The selection of which template to use should be based on the 
spatial resolution across all subjects. 
 
Figure 2-1:  Shows a trans-axial montage of the 2mm 152 T1 MNI template ranging from slice 14 to 54 in increments of 5 
slices. T1 MRIs are warped to this space and the transformation is applied back to the AV1451 scan following fitting to the 
MRI. 
2.2  Alzheimer’s Disease and Tau Pathology 
AD is the most prevalent form of dementia, accounting for between 60% and 70% of 
all cases[23]. AD is characterized by the initially slow impairment of cognitive functions 
which rapidly worsens over time. The exact cause of AD is still in dispute [24], but a leading 
hypothesis involves the accumulation of neurotoxic β-amyloid plaques in the grey cortex 
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[25]. This accumulation is thought to drive the hyper-phosphorylation of tau protein. Tau 
typically reinforces microtubule structure in the axons of neurons, but hyper-
phosphorylation causes tau to become unstable, breaking apart and forming PHFs. This leads 
to apoptosis and eventual regional atrophy [26]. This eventually translates to cognitive 
decline as measured in the clinic through tests such as the mini-mental state exam (MMSE). 
Typical tau propagation has been mapped by Braak and Braak in 6 distinct stages 
based on regional accumulation [27]. The first two stages involve the transentorhinal region, 
the middle two stages involve the limbic region such as the hippocampus, and the last two 
stages involve the rest of the grey cortex. The stages are visualized in Figure 2-2. 
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Figure 2-2:  Braak tau staging. [27] The six stages are separated based on regions with tau accumulation as well as 
the intensity of tau within that region. Stages 1 and 2 are local to the transentorhinal boundary. Stages 3 and 4 involve 
limbic areas such as the hippocampus. Stages 5 and 6 involve the majority of the grey cortex having tau accumulation.  
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2.3 AV1451 
 AV1451 is an 18F-labeled ligand with high binding affinity to PHFs in the grey cortex. 
AV1451 has been shown to have minimal white matter affinity while binding to PHFs more 
than 27 times more than beta amyloid plaques [28]. Test-retest reliability was established in 
15 subjects with a Pearson’s R correlation of 0.86 and p value less than 0.001 [29]. 
 
Figure 2-3:  Differential diagnostic imaging between a A) clinical normal older control and a B) older patient with AD [9]. 
The cognitively normal subject has no AV1451 uptake topology within the brain while the AD patient has clear uptake 
patterns throughout the grey cortex with intense asymmetric uptake in the left lateral temporal lobe. 
 Differential imaging is apparent across clinical groups as seen in Figure 2-3: row A 
shows a clinically normal older control with no apparent uptake within the cerebrum while 
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row B shows a subject with mild Alzheimer’s disease with major uptake asymmetrically in 
the temporal lobe and moderate uptake in the frontal lobe. Both images have been 
normalized with respect to the grey cerebellum and viewed in an SUVr range of 1 to 2. 
2.4 MUBADA and VoBADA 
 MUBADA was introduced in [10] and can be seen as an extension of barycentric 
discriminant analysis (BADA). BADA itself incorporates the grouping feature seen in 
discriminant analysis where subjects are classified based on a priori defined groups and the 
goal of extracting meaningful separation qualities as found in mean-centered partial least 
squares correlation (MC-PLSC). BADA deviates from these methods by allowing multi-
colinearity and an evaluation method to determine the accuracy of group classification. 
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Figure 2-4: The general process of running MUBADA and VoBADA. A) The voxels are loaded into a data matrix with 
subjects on the rows and voxel position ono the columns. B) A second data matrix consisting of the average images based on 
the a priori groups is generated. C) Bootstrapping the decomposition can help determine significance of the eigenvalues and 
eigenvectors. D) Regions (MUBADA) or voxels (VoBADA) can be projected into partial inertias which describe the degree 
of group separation. Significance can be determined from C) to extract voxels which move in the direction of disease. 
 BADA is based on creating a factor space derived from group barycenters, or 
weighted averages, onto which the original observations for each subject and loading scores 
for the variables (or in this case the voxels) can be projected. By grouping the variables using 
a priori information (e.g. region in the grey cortex), BADA is extended into MUBADA. Then, 
the contribution each region has in group separation can be evaluated in a map of partial 
inertias or separation factors. An important note is that deciding what weights to use is data-
specific, and the analysis can be performed normally even if all subjects within the groups 
are provided the same weight (e.g. the reciprocal of the number of subjects within that 
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group). If the variable, brain region groups are replaced by individual voxels, MUBADA 
converts to voxel-wise barycentric discriminant analysis (VoBADA). Excluding the 
difference between variable groupings, there are no other meaningful differences. The 
process is visualized in Figure 2-3. 
 To run VoBADA, data must first be stored in a n by m data matrix X where n is the 
number of subjects and m is the number of voxels. X is then normalized with care taken to 
the selection of the normalization method—two different normalization procedures can 
wind up having drastically different conclusions. Two common normalization techniques are 
applying subject-specific weights such that the sum of each subject’s voxels equals 1 and 
creating Z scores based on the sample population. The choice of normalization is data-
specific and must make sense in the context of the analysis. After normalization, X is 
centered based on the mean image to create Xc. A separate l by m data matrix, R, is 
constructed based on the uncentered X and stores the average images for each l group R is 
also centered to create Rc. Singular value decomposition is then applied on Rc in order to 
solve Equation 2. 
RC = UΣVT                                                                      (Eqn 2) 
U is a l by l matrix containing the left eigenvectors of the decomposition while V is a m by m 
matrix containing the right eigenvectors of the decomposition. Σ is a l by m diagonal matrix 
containing positive values corresponding to the eigenvalues for each principal component. 
The problem with SVD is it becomes increasingly computationally intensive as the number 
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of subjects and variables grows, and with approximately 100,000 variables representing a 
whole brain in a PET image in MNI space, SVD becomes impossible. To circumvent this 
issue, a generalized principal component analysis (GPCA) can be performed on RC. 
RC = PΔQT                                                                (Eqn 3) 
Equation 3 shows the GPCA of RC. Δ is a k by k matrix of k singular values corresponding to 
the k principal components. P is a l by k matrix of left eigenvectors while Q is a m by k 
vector of right eigenvectors. Group factor scores, F, can be calculated by Equation 4. 
F = PΔ                                                                   (Eqn 4) 
Loadings corresponding to the voxels can be calculated by Equation 5. 
G = QΔ                                                                     (Eqn 5) 
The collection of voxel-wise eigenvectors will henceforth be referred to as the “eigenbrain.” 
The “eigenbrain” can be conceptualized as a map of vectors for each brain voxel: the 
magnitude corresponds to the degree of group separation while the direction points along the 
factor space towards the groups the voxel relates. For example, a positive voxel with a large 
weight would represent that this voxel is most likely to associate with disease and be a strong 
separator of cohorts. This is all dependent on the factor space that is created, however. 
 Each subject can be projected onto the factor space from XC by Equation 6. 
H = XQ                                                                    (Eqn 6) 
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Classification accuracy can be assessed by comparing the distance of each subject’s factor 
score to each of the group factor scores. Classification accuracy can then be assessed by 
assigning subjects to groups based on the minimum distance between a subject’s factor score 
and each of the group’s factor scores. To better project the classification accuracy to the 
entire population, subjects can be jackknifed onto the factor space in a leave-one-out fashion: 
the factor space is iteratively calculated by leaving one subject out at each time. Due to the 
jackknifed samples representing the population, the results will be referred to as random 
effects. Determining the group separation weights is accomplished by squaring the elements 
in G and multiplying by a weighting factor corresponding to the reciprocal of the number of 
voxels. 
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3. SPECIFIC AIMS 
 The main goal of this project is to assess the differential diagnostic potential of 
AV1451 PET images through VoBADA to better understand regions which can be used to 
determine an AD-like typical pattern that can separate AD patients from normal and 
cognitively impaired subjects. Since amyloid status is a hypothetically key component of AD 
development and progression, the amount of amyloid in each subject’s brain will be 
estimated through Amyvid PET images. 
1. Significance of  Principal Components 
As MUBADA is based on forming a factor space based on mean images, the 
eigenvalues from the singular value decomposition only relate to the amount 
of variance in each dimension and do not speak to the significance of each 
dimension. To determine the significance of each dimension, three separate 
tests will be performed in decreasing order of subjectivity: the Scree test, 
evaluating the percent of overall variance contribution, and bootstrapping the 
SVD. 
2. Evaluation of Group Separation Accuracy 
Each subject can be loaded onto the mean-generated factor space to assess the 
quality of group separation. Two types of projections will be evaluated: fixed 
and jackknifed. Fixed shows how well the groups separate within the data 
sample while jackknifed provides a broader perspective on how the population 
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might fair in group separation. For both projections, confusion tables will be 
generated and used to calculate accuracy for each group pair. Accuracy 
measures will then be compared against chance categorization by a Chi-
squared test. Finally, accuracy measures will be compared to diagnostic accuracy 
within the clinic. 
3. Extraction of Significant “Eigenbrain” 
In addition to loading subjects onto the factor space, voxel or regional values 
can be loaded and assessed for separation power through the creation of a 
partial inertia image. This image is based on the squared right eigenvector of 
the SVD. However, as the image is squared, only magnitude is represented in 
this image. To extract only the voxels weighted for separation and move in the 
direction of disease progression, the pseudo-standard scores generated from 
the bootstrapped  
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4. MATERIALS AND METHODS 
4.1  Materials 
MUBADA is based on code written by Dr. Hervé Abdi at the University of Texas at 
Dallas. Modifications were made in MATLAB R2006b in a Windows 7 environment. PET 
processing was conducted in both FSL 5.05 and SPM8 in a CentOS environment. 
4.2 Methods 
An expected 230 subjects were to be enrolled in the study with a proposed break-up 
of 80 mild cognitive impairment (MCI) subjects and 70 AD subjects with images acquired at 
30 national PET centers. For each site, image quality was assessed by imaging and analyzing a 
Hoffman brain phantom. These phantoms have an expected grey-to-white activity ratio of 3 
to 1. Deviations from this ratio provide a sense of the noise characteristics for that site’s 
scanner. In addition, each site’s phantom is compared to a template phantom to estimate the 
site’s point spread function (PSF). A library of candidate phantom templates convolved with 
Gaussian filters were generated in SPM with trans-axial and z smoothing ranging from 4 to 
14 mm in increments of 0.2 mm. Similarity was assessed by using the sum of squared distance 
(SSD) equation in Equation 7. The algorithm compares each of the N shared non-zero, non-
NaN voxels in both the site phantom and the j library image and computes an SSD value for 
each library image. The smoothing parameters associated with the library image that has the 
lowest SSD are selected as the PSF for that site. 
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SSDj =  ��Pi − Lij�2N
i=1
                                                       (Eqn 7) 
Amyvid scans were acquired as a screening tool to determine the potential for 
subjects to have Alzheimer’s disease. Subjects were given 10 mCi of Amyvid and were 
imaged 50 minutes post-injection. Scans were reconstructed into two 5 minute frames based 
on site-specific image reconstruction protocols. These frames were averaged in MIM and the 
average image was then exported. Due to alterations within MIM, the image is checked and 
corrected in MRICro to make sure the voxel dimensions are consistent for the imaging site 
and that the brain is oriented properly. The image is then non-linearly warped to a template 
AV45 image using SPM. The fitted image is compared to the template image by assessing the 
degree of overlap of the brain boundary—images with more or less than two voxels within 
the template brain boundary have their brains extracted by applying a mask in SPM and refit 
to the template. If subjects fail QC again, they are skull stripped using brain extraction (BET) 
software in MRICro and refit to the template. Further failure is assessed on a case-by-case 
basis. The final fit is then imported into MATLAB where the average of grey cortical regions 
counts is divided by the average cerebellum counts to create an SUVr. Values greater than 
1.1 are deemed amyloid positive while values less than 1.1 are deemed amyloid negative. 
On a separate visit, subjects were injected with 10 mCi of AV1451. Images were 
acquired 80 minutes post-injection and were reconstructed into four 5 minute frames. This 
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was repeated 110 minutes post-injection. On a separate visit, a T1 MRI was acquired for each 
subject. 
The T1 MRIs were skull stripped and segmented into grey matter, white matter, and 
cerebrospinal fluid (CSF) tissue classes in SPM. This process also warps the MRI to a 
Montreal Neurological Institute (MNI) template. AV1451 Images were then motion 
corrected using FLIRT in FSL and an average image was created. The mean image is skull 
stripped and linearly warped to the skull stripped T1 MRI. The MRI to atlas transformation is 
then applied to the AV1451 image in MRI space. All intermediate and atlas space images are 
uploaded to MIM for QC. This involves checking the brain boundary of the AV1451 PET 
image in atlas space and the T1 MRI in atlas space. Subjects who failed this QC were 
subjected to a less regularized fit using Advanced Normalization Tools (ANTs). 
Subjects which passed all QC points were used to create a study-specific brain mask. 
This was accomplished by averaging each subject’s brain masks as determined by their grey 
and white matter MRI segmentations. 
The average brain mask was used to extract brain voxels from grey cerebellum-
normalized AV1451 scans based on a binary map where a 1 indicates voxels which will be 
included for analysis. Vectorization, the process of extracting elements in a matrix and laying 
them out in a vector, is used to convert the data into a n x m data matrix X with n subjects 
for the rows and m voxel locations for the columns. Voxel locations with zero or NaN values 
were removed from the matrix. Subjects were classified into groups based on paired amyloid 
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status and clinical diagnosis. A separate matrix n x l matrix Y was created to assign each 
subject to one of the l groups by designating a 1 in the column for that subject’s group. The 
data matrix X was then centered based on the mean image. A separate l x n data matrix R was 
created by averaging images in X based on their group assignment in Y. This matrix was also 
centered.  
Specific Aim 1: Significance of Principal Components 
 Following SVD, the eigenvalues were assessed to determine the significant 
dimensions which contribute to the variance within the dataset. Three separate tests are 
utilized for assessing dimension significance: the Scree test, evaluation of overall variance 
contribution, and bootstrapping the decomposition. 
 The Scree test involves plotting the eigenvalues for each dimension and determining 
the point of diminishing returns—that is, where the increase in dimensions has minimal 
effect on the increase in explained variance. Assessing each dimension’s contribution to 
variance is accomplished by dividing each eigenvalue by the total sum of the eigenvalues. 
Dimensions with a cumulative sum of 95% variance will be considered. Finally, 
bootstrapping involves resampling the subjects within each group with replacement and 
iteratively running the SVD to determine standard deviation values for each eigenvalue. 
Pseudo-standard scores can be calculated by dividing each eigenvalue by the standard 
deviation. Applying a threshold of 3 eliminates dimensions with low signal-to-noise. After 
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running all three tests, dimensions will be preserved by giving preference to the less 
subjective methods. 
Specific Aim 2: Evaluation of Group Classification Accuracy 
 Subjects were projected onto the factor space generated by R and classification 
accuracy was assessed by assigning each subject’s factor score to the closest group barycenter. 
The accuracy in separating two groups was determined by Equation 5: 
Accuracy = True Group A + True Group BTrue Group A + False Group A + False Group B + True Group B              (Eqn 8) 
To evaluate the classification performance on the general population, the decomposition is 
jackknifed. This is an iterative procedure where each subject is left out of the calculation, the 
decomposition was reanalyzed, and new group barycenters were calculated. Subject factor 
scores were loaded based on the new factor space and new classifications were assessed. 
Classification accuracy was again determined by Equation 5.The Chi-square test was utilized 
to determine whether the classification was better than chance. This was accomplished by 
subtracting each measured accuracy by the expected accuracy, 50%, squaring the value, and 
dividing by 50%. Each Chi-square measure was then summed to get the total Chi-square 
value from which a p value was derived. 
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Specific Aim 3: Extraction of Significant “Eigenbrain” 
 Voxels which affect group separation can be extracted based on Equation Y. Since the 
separation weights in the partial inertia map are squared values, they say nothing about the 
direction the weights point. In order to only extract the voxels which contribute both to 
group separation and point in the direction of disease, the SVD is again bootstrapped to 
extract resampled “eigenbrain” values and created standard deviations for each voxel. A 
lower threshold of 3 is applied to the pseudo-standard scores to extract the meaningful 
voxels. These voxels are then related to regions known to contribute to Alzheimer’s disease 
and the propagation of PHFs.  
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5. RESULTS AND DISCUSSION 
5.1      Data Acquisition and Analysis 
A total of 222 subjects were enrolled in the study. The breakdown of participants is as 
follows: 16 young controls (YCN, average age 29 +/- 10), 58 old healthy controls (OCN, 
average age 69 +/- 20), 97 mild cognitive impairment subjects (MCI, average age 71 +/- 18), 
and 51 Alzheimer’s disease subjects (AD, average age 74 +/- 18). 
Estimating the phantom resolution across sites revealed that the average trans-axial 
resolution was 7 mm +/- 1.53 mm (min of 6 mm and max of 8 mm) and the average z 
resolution was 7.21 mm +/- 2.19 mm (min of 6 mm and max of 10.4 mm). The disparity 
between scanner PSFs can induce error when comparing images across multiple sites. A 
possible work-around would be to smooth all images to reach the maximum level of 
smoothing. However, this can underestimate areas of high uptake and overestimate areas of 
low binding such as white matter. 
 Pairing the clinical status with the amyloid status from the Amyvid images led to the 
creation of groups detailed in Table 5-1. One subject dropped out of the study following their 
AV1451 scan, bringing the total subjects to 221. 
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Table 5-1: Shows the breakdown of subjects within the study based on clinical diagnosis and amyloid status. Due to the low 
number of group members, the OCN amyloid positive group is removed from the study. In addition, the YCN group is 
removed due to the concern that there would be too much variance between them and all other scans. 
 
AB- AB+ 
YCN 16 0 
OCN 55 3 
MCI 43 54 
AD 16 34 
 
 The AV1451 scans were sent through the aforementioned pipeline and uploaded to 
MIM for visual QC. Out of the 221 subjects, one required a higher fit. 
 
Figure 5-1: Shows an example of the image QC process using MIM software. Each subject’s AV1451 image in atlas space is 
compared to the subject-specific MRI in atlas space. Fit quality is assessed by examining the brain boundaries between the 
two scans. A good quality fit is determined to be within plus or minus 2 voxels of the MRI brain boundary. Subjects which 
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fail this stage are passed through a more deformable fit such as the example shown. Subjects which fail this second fit are 
assessed on a case-by-case basis. 
The brain mask was created by combining each subject’s grey and white matter tissue 
probability maps to create a probability map for brain tissue, averaging all brain probability 
maps, and then applying a threshold of 0.5 to ensure the tissue class was in fact brain. Figure 
5-2 shows the average brain mask overlaid on an average MRI template. 
 
Figure 5-2: The average brain mask in purple used to extract voxels from the AV1451 PET images. Color has no meaning 
other than it allowed the volume to be viewed in MIM software. The average brain mask expectedly fits the brain boundary 
of the average study MRI. 
Modifications were made to pre-existing scripts to optimize for using single-voxel 
groups—these can be found in the Appendix.  
Following examination of the groups described in Table 5-1, the YCN and OCN- groups were 
dropped from the analysis. The YCNs have too little uptake and may skew the results to only 
show separation against YCN rather than meaningful separation between disease states. The 
OCN- group was dropped since there were only 3 subjects in the group and would not have 
sufficient power. The remaining subjects were vectorised and VoBADA was ran as 
aforementioned. While the number of principal components corresponds to the number of 
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groups in the analysis, only 4 components were found since the 5th had too few variance to 
provide any meaningful information as specified by a pre-determined threshold. 
5.2  Specific Aim 1: Significance of Principal Components 
Plotting the eigenvalues for each of the components in Figure 5-3 shows a clear separation 
between the first and other dimensions. This suggests that including dimensions after 
dimension 1 will not provide any more meaningful information in explaining the variance of 
the dataset. 
 
Figure 5-3: Shows the Scree plot for the 4 principal components. There is a clear point of diminishing returns after 
dimension 1, indicating that no more meaningful information could be gained by exploring further dimensions in the 
context of group separation. 
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 Examining the percent variance each dimension contributes in Table 5-3 further 
supports this notion.  
Table 5-2: Shows the contribution of variance for each of the 4 dimensions. Dimension 1 dominates the total amount of 
variance explained  
Dimension % Variance 
1 97.9547 
2 1.0112 
3 0.7959 
4 0.2382 
 
Dimension 1 is greater than the threshold of 95% total variance. Bootstrapping the creation 
of the factor space 1000 times led to the histograms for each of the dimensions as seen in 
Figure X. Regardless of the dimension, the bootstrapped samples appear relatively normal in 
their distribution with slight right skew in dimensions 2, 3, and 4. Table 5-3 shows the 
breakdown of the pseudo-standard scores created using the standard deviation of the 
bootstrapped samples. Dimensions 1 and 3 are the only dimensions whose pseudo-standard 
scores survive a threshold of 2. Taking into consideration the Scree test, the percentage of 
explained variance, and the bootstrapped standard scores, Dimension 1 is the only dimension 
worth investigating. This does not imply that the other dimensions do not contain 
interesting explanations of variance—Dimension 3 may help explain anomalies seen in a 
select few subjects yet is too weak to show up globally. Rather, Dimension 1 should be 
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viewed as the sole dimension which can explain the separation of the clinical groups and the 
only dimension which satisfies the goal of this project. 
 
Figure 5-4: Shows the histograms of the bootstrapped eigenvalues for all 4 dimensions after 1000 iterations. Dimension 1 
appears to have a normal distribution while the other dimensions are right skewed. 
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Table 5-3: Shows the pseudo-standard scores for the four dimensions after bootstrapping. Dimensions 1 and 3 are the only 
dimensions to survive after applying a threshold of 2. This does not mean that the other dimensions do not explain 
interesting characteristics, only that dimensions 2 and 4 are not important for the goal of separating cohorts. 
Dimension 
Pseudo-
Standard 
Score 
1 4.3181 
2 1.5717 
3 2.6321 
4 1.7848 
 
5.3  Specific Aim 2: Evaluation of Group Classification Accuracy 
 Figure 5-5 shows the fixed effects group means and 95% confidence intervals for the 
first dimension. There is a clear rise in Dimension 1 factor scores as the groups progress to 
sicker subjects, but the wide-range of across-subject variability is clear in the overlapping 
confidence intervals. This is most likely due to the subjects in the amyloid positive groups 
encompassing a wide range of disease states. This could be corrected by identifying sub-
categories of both amyloid positive MCI and AD groups to better differentiate the subjects 
and reduce within-group variance. Table 5-4 shows the numbers of subjects that belong to 
the group specified in the column yet were classified as belonging in the group specified by 
the row. Table 5-4 also shows the classification accuracy calculated by Equation 5.  The Chi-
square test on the fixed effects accuracy resulted in a p value less than 0.05 (p = 0.0139) 
indicating that the classification is significantly different than classifying the subjects 
randomly. 
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Figure 5-5: The fixed effects projection of the factor scores for all four dimensions including the mean of each group and 
their 95% confidence interval. The amyloid negative groups form a super-cluster which indicates that there is no 
meaningful difference between them. The averages of the amyloid positive MCI and AD groups increase in factor score as 
disease state worsens, but there is too much within-group variability to discern a significant difference. This may indicate 
that there are sub stages of diseases within the MCI positive and AD positive populations. 
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Table 5-4: The number of subjects which were classified into each of the groups based on fixed effects modeling with 
respect to their original group as well as the classification accuracy for correctly assigning subjects to their diagnostic 
category. Red cells correspond to subjects correctly assigned to their cohort. Accuracy is high when comparing amyloid 
negative groups to amyloid positive groups—the exception is comparing amyloid positive and negative ADs as the accuracy 
of separating these groups is 82.05%. 
  Fixed Effects Model 
  Actual Class 
  OCN- MCI- AD- MCI+ AD+ 
OCN- 
(n=55) 
22 10 1 9 0 
MCI- 
(n=43) 
21 25 1 2 0 
AD- 
(n=16) 
6 5 12 19 7 
MCI+ 
(n=54) 
6 3 2 11 7 
AD+ 
(n=34) 
0 0 0 13 20 
  Accuracy 
  OCN- MCI- AD- MCI+ AD+ 
OCN- 
(n=55) 
-- 60.26 82.93 68.75 100.00 
MCI- 
(n=43) 
60.26 -- 86.05 87.80 100.00 
AD- 
(n=16) 
82.93 86.05 -- 52.27 82.05 
MCI+ 
(n=54) 
68.75 87.80 52.27 -- 60.78 
AD+ 
(n=34) 
100.00 100.00 82.05 60.78 -- 
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Figure 5-6: The random effects projection of the factor scores for all four dimensions including the mean of each group and 
their 95% confidence interval. This plot shows a similar story to the fixed effects projection. 
Figure 5-6 shows the random effects group means and 95% confidence intervals for 
the first dimension. A similar layout is seen as in the fixed effects projection. Table 5-5 shows 
a confusion matrix for the classification of the fixed effects projection—here, rows 
correspond to the groups the subjects were assigned while the columns correspond to the 
subjects’ actual group. Classification accuracy as determined by Equation 5 is also detailed in 
Table 5-5.  The Chi-square test on the fixed effects accuracy resulted in a p values greater 
than 0.05 (p = 0.0528) indicating that the classification is not significantly different than 
classifying the subjects randomly. 
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Table 5-5: The number of subjects which were classified into each of the groups based on random effects modeling with 
respect to their original group as well as the classification accuracy for correctly assigning subjects to their diagnostic 
category. Red cells correspond to subjects correctly assigned to their cohort. Accuracy is again high when comparing 
amyloid negative groups to amyloid positive groups—this time the accuracy in separating AD negatives from AD positives is 
77.78% 
  Random Effects Model 
  Actual Class 
  OCN- MCI- AD- MCI+ AD+ 
OCN- 
(n=55) 
18 18 5 9 0 
MCI- 
(n=43) 
24 15 7 2 0 
AD- 
(n=16) 
7 7 2 19 6 
MCI+ 
(n=54) 
6 3 2 10 9 
AD+ 
(n=34) 
0 0 0 14 19 
  Accuracy 
  OCN- MCI- AD- MCI+ AD+ 
OCN- 
(n=55) 
-- 44.00 62.50 65.12 100.00 
MCI- 
(n=43) 
44.00 -- 54.84 83.33 100.00 
AD- 
(n=16) 
62.50 54.84 -- 36.36 77.78 
MCI+ 
(n=54) 
65.12 83.33 36.36 -- 55.77 
AD+ 
(n=34) 
100.00 100.00 77.78 55.77 -- 
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These accuracy measures are relative to the entire diagnostic/amyloid status battery and are 
prone to miss classification ability on an individual pair level. For instance, the most 
important group pair to assess classification accuracy is the AD positive and negative pair. 
This pair represents a physician having to make a judgment between AD and some other 
form of dementia or cognitive impairment. [30] reports a positive predicative value for 
diagnosing AD as between 46.0% and 83.3% depending on the tests available to them. In 
addition, they report that 39% of subjects who were clinically diagnosed as not having AD in 
fact met threshold requirements in histopathological staining to be diagnosed as having AD. 
This might help explain why some AD negative subjects are misclassified as being AD 
positive. 
5.4  Specific Aim 3: Extraction of Significant “Eigenbrain” 
The partial inertia image seen in the trans-axial slice montage in Figure 5-7 was 
generated by squaring the “Eigenbrain” and dividing by the total number of voxels. The 
hottest voxels in the temporal-occipital-parietal regions contribute most to group separation 
with some additional involvement in the frontal lobe. This is on par with the brain regions 
most commonly associated with AD. In addition, there is a laterality effect evident in Figure 
5-7: the left hemisphere has a greater extent of higher weights than the right hemisphere. 
One explanation for this effect is that handedness could influence the pathways through 
which PHFs progress through the cortex. This has yet to be proven, however, and would 
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require further study. The laterality may also be due to the inherent behavior of neural 
networks which could be assessed using functional connectivity MRI (fcMRI). 
 
Figure 5-7: A trans-axial montage of the partial inertia map from dimension 1 with high weights prominently in the 
temporal, parietal, and frontal lobes overlaid on an MRI template. Substantial weighting is located in the left lateral 
temporal. 
To assess whether the hottest voxels are pointing towards the AD+ group in the “eigenbrain”, 
the factor space was iteratively generated by bootstrapping the group assignment. 
 
Figure 5-8: Shows a trans-axial montage of the significant voxels which survived after bootstrapping overlaid on a MRI 
template. The same voxels which have high weights in Figure 5-7 survive after bootstrapping which suggests that all 
meaningful weights move in the direction of disease progression. 
Figure 5-8 shows the voxels which remain after applying a threshold of 3 to the bootstrapped 
pseudo-standard scores. There is clear congruence between the intense weights in Figure 5-7 
and the significant voxels in Figure 5-8. This suggests that all voxels which meaningfully 
separate the groups all point in the direction of disease. 
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6. CONCLUSION AND FUTURE DIRECTION 
 In conclusion, AV1451 has been shown to have potential in the differential diagnosis 
of clinical groups paired with amyloid status through the application of VoBADA. Extracting 
the main principal components was accomplished by combining the results from the Scree 
test, percentage of total variance, and bootstrapping to create standard scores. Dimension 1 
was seen as the sole contributor to meaningful variance across diagnostic groups. Projecting 
each subject’s factor scores through both fixed effects and random effects models allowed for 
the evaluation of classification accuracy based on the distance between the subject’s loadings 
and each of the group means. Fixed effects classification was found to be significantly better 
than chance through the Chi-square (p = 0.0139) test while random effects classification was 
not (p = 0.0538). The accuracy of separating amyloid positive ADs from amyloid negative 
ADs in the random effects model, 77.78%, was on the high end for reported accuracy when 
diagnosing patients in the clinic. Voxels which could help better distinguish between groups 
were created from the “eigenbrain” and significant voxels were extracted through 
bootstrapping. While significant voxels were found in the frontal, temporal, parietal, and 
occipital lobes, the left lateral temporal dominated the weights. Accuracy in separating 
cohorts based on clinical diagnosis and amyloid status may not be high in the whole brain, 
but focusing on the voxels specified in the significant eigenbrain would theoretically 
improve the separation quality of the cohorts. 
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 One next step is to evaluate the effect of PVC on the separation quality and resultant 
significant “eigenbrain.” The spread of scanner resolutions may have induced 
underestimations in images from sites with larger PSFs, therefore diminishing the 
contribution that voxel could have if it belonged to an amyloid positive group. In addition, 
PVC could help more accurately model the counts in the grey cortex and help to eliminate 
the total number of voxels in the analysis. Another step would be to validate using the 
significant “eigenbrain” to categorize cross-sectional AV1451 images into paired clinical 
diagnosis and amyloid status groups. This would increase confidence that the analysis 
method is working properly in extracting meaningful voxels, but that the voxels themselves 
are important to separating the groups. A final step would be to implement this method in a 
longitudinal, potentially mixed effects, fashion with the goal of extracting subject-specific or 
disease-stage specific weights that can best quantify change in tau. 
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8. APPENDIX 
#This code contains sections to import data as well as call functions written 
#by Herve Abdi as well as modifications made in house to run VoBADA. Scripts 
#by Herve Abdi can be acquired on his site  http://www.utdallas.edu/~herve/ 
 
clear,clc 
  
addpath('/usr/local/spm8') 
addpath('../AV1451_MUBADA/MuSuBADA_V4') 
  
pd = dir('11*.nii'); 
group = repmat(1:2,1,60); 
  
rinfo = spm_vol('blcere_all.img'); 
r = double(logical(spm_read_vols(rinfo))); 
  
br_info=spm_vol('../AV1451_MUBADA/BrainMask.nii'); 
br=double(logical(spm_read_vols(br_info))); 
ind=find(br==1);l=length(ind); 
  
X = zeros(0,l); 
for i = 1:length(pd) 
    p_info = spm_vol(pd(i).name); 
    p = double(spm_read_vols(p_info)); 
    p(isnan(p)) = 0; p(p < 0) = 0; 
    list = sort(nonzeros(p.*r)); 
    list = list(round(length(list)/3)+1:length(list)-round(length(list)/3)); 
    X = [X;[p(ind)./mean(nonzeros(p.*r.*br))]']; 
end 
  
badind = find(prod(X)==0); 
X(:,badind)=[]; 
ind(badind)=[]; 
  
  
Y = repmat([0 1; 1 0],60,1); 
  
b = ones(size(Y,2),1)*(1/size(Y,2)); 
w = ones(size(X,2),1)*(1/size(X,2)); 
Z = l; 
nB=Z; 
Ym = Y.*repmat((1./sum(Y)),size(Y,1),1); 
R = Ym' * X; 
Rc = R - repmat(mean(R),size(R,1),1); 
Xc = X - repmat(mean(X),size(X,1),1); 
[F,d,G] = get_F_G(Rc,b,w); 
lambda = d.^2; 
taus = (lambda/sum(lambda))*100; 
  
F_sup = getIndividualFS(Xc,w,size(X,1),G,d,size(X,2),lambda); 
PI_blocks = zeros(size(G)); 
for i = 1:size(G,2) 
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    PI_blocks(:,i) = w(i).*(G(:,i)).^2; 
end 
Gnorm=(1/size(X,2))*G.*repmat((lambda.^(-1/2))',size(X,2),1); 
F_sup_blocks = zeros(size(X,1),size(F,2),size(X,2)); 
for i = 1:size(X,2) 
    F_sup_blocks(:,:,i) = 1./w(i).*(Xc(:,i)*Gnorm(i,:)); 
end 
  
samples = 1000; u = zeros(1,samples); s = zeros(1,samples); v = 
zeros(size(X,2),samples); 
for i = 1:samples 
    disp(i); 
    subjBoot = zeros(size(Y,1),1); 
    for j = 1:size(Y,2); 
        in = find(Y(:,j) == 1); 
        subjBoot(in) = randsample(in,length(in),'true'); 
    end 
    X2 = X(subjBoot,:); 
    R = Ym'*X2; 
    Rc = R - repmat(mean(R),size(R,1),1); 
    [ud,sd,vd] = get_F_G(Rc,b,w); 
    u(i) = ud(1); 
    s(i) = sd(1).^2; 
    v(:,i) = vd(:,1); 
end 
  
  
[GroupsAssigned_fixed,ConfusionMatrix_fixed] = 
confusion(F_sup,F,size(Y,2),Y); 
[F_sup_jack,F_jack,proj_F_jack,F_sup_jackrec,Dsup_Jack] = 
jackknife(X,Y,G,d,w,b); 
[GroupsAssigned_Jack,ConfusionMatrix_Jack] = 
confusionComputation(Dsup_Jack,size(Y,2),Y); 
